Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma.
MGMT promoter methylation status
adult
gross total resection
pilocytic astrocytoma
progression-free survival
tumor location
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Jul 2019
29 Jul 2019
Historique:
received:
01
07
2019
revised:
25
07
2019
accepted:
25
07
2019
entrez:
1
8
2019
pubmed:
1
8
2019
medline:
1
8
2019
Statut:
epublish
Résumé
In adults, pilocytic astrocytomas (PA) account for less than 2% of gliomas, resulting in uncertainty regarding the clinical course and optimal treatment, particularly in cases where gross total resection (GTR) could not be achieved. Moreover, information on molecular markers and their prognostic impact is sparse. In order to improve risk stratification, we analyzed our institutional series of 58 patients aged 17 years and older with histology-proven intracranial PA World Health Organization grade I for clinical and molecular prognosticators. Anaplastic and NF1-associated tumors were excluded. O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status was determined by pyrosequencing or 450k/850k DNA methylation array. A univariate log-rank test and multivariate StepAIC were applied to identify prognostic factors. The median age was 30 years (range 17-66). Tumors were located in the cerebral/cerebellar hemispheres, midline structures and cerebello-pontine angle in 53%, 38% and 9%. MGMT promoter methylation was present in eight patients (14%). GTR (39/58 patients) significantly reduced the likelihood of tumor recurrence (
Identifiants
pubmed: 31362435
pii: cancers11081072
doi: 10.3390/cancers11081072
pmc: PMC6721291
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Anni-Hofmann-Foundation
ID : N/A
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Cancer Res. 1999 Feb 15;59(4):793-7
pubmed: 10029064
N Engl J Med. 2000 Nov 9;343(19):1350-4
pubmed: 11070098
J Neurosurg. 2003 Jun;98(6):1170-4
pubmed: 12816259
Oncogene. 2004 Jan 8;23(1):1-8
pubmed: 14712205
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Br J Neurosurg. 2004 Dec;18(6):613-6
pubmed: 15799194
Cancer. 2007 Dec 15;110(12):2799-808
pubmed: 17973253
Acta Neuropathol. 2009 Sep;118(3):401-5
pubmed: 19543740
J Neurooncol. 2010 May;97(3):311-22
pubmed: 19841865
Brain Pathol. 2010 Jan;20(1):245-54
pubmed: 19903171
Acta Neuropathol. 2010 May;119(5):641-9
pubmed: 20044755
Acta Neuropathol. 2011 Mar;121(3):397-405
pubmed: 21274720
Cancer. 2011 Sep 1;117(17):4070-9
pubmed: 21391213
Clin Cancer Res. 2011 Jul 15;17(14):4790-8
pubmed: 21610142
Acta Neuropathol. 2011 Jul;122(1):11-9
pubmed: 21638088
J Neuropathol Exp Neurol. 2012 Jan;71(1):66-72
pubmed: 22157620
Cell Mol Life Sci. 2012 Jun;69(11):1799-811
pubmed: 22159586
Cancer. 2012 Sep 1;118(17):4201-11
pubmed: 22294349
J Neurooncol. 2012 May;108(1):187-93
pubmed: 22367412
J Child Neurol. 2013 May;28(5):625-32
pubmed: 23439714
Neuro Oncol. 2014 Jun;16(6):841-7
pubmed: 24470550
Nat Rev Neurol. 2014 Jul;10(7):372-85
pubmed: 24912512
Neurooncol Pract. 2015 Dec;2(4):199-204
pubmed: 26640699
J Neurosurg Pediatr. 2016 May;17(5):569-72
pubmed: 26722760
J Mol Diagn. 2016 May;18(3):350-361
pubmed: 26927331
J Neurooncol. 2017 Jan;131(1):163-175
pubmed: 27743145
World Neurosurg. 2018 Feb;110:276-283
pubmed: 29180079
World Neurosurg. 2018 Apr;112:e881-e887
pubmed: 29427814
Oncol Lett. 2018 Feb;15(2):1600-1606
pubmed: 29434855
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Acta Neuropathol. 2018 Aug;136(2):273-291
pubmed: 29564591
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Br J Neurosurg. 2019 Jun;33(3):343-347
pubmed: 30653383
Childs Nerv Syst. 2019 May;35(5):801-805
pubmed: 30770993